Anti-nucleolin aptamer AS1411 (formerly known as AGRO100)

Drug Overview

The medication known as AS1411 is a cutting-edge type of “Smart Drug” used in the field of oncology. It is not a standard chemotherapy drug or a traditional antibody. Instead, it belongs to a new class of medicines called aptamers. Think of an aptamer as a “chemical antibody”—a short, single strand of DNA that has been folded into a specific 3D shape to find and lock onto cancer cells with high precision.

Here are the key details about this agent:

• Generic Name: Anti-nucleolin aptamer AS1411 (formerly known as AGRO100).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: DNA Aptamer / Nucleolin Inhibitor / Targeted Therapy.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It is not yet FDA-approved for standard public use, but it has been studied in Phase 1 and Phase 2 clinical trials for various cancers.

What Is It and How Does It Work? (Mechanism of Action)

The Molecular “Key”

AS1411 is specifically designed to recognize the nucleolin protein found on the surface of cancer cells. Here is how it works at the molecular level:

1. Recognition and Binding: Once infused into the bloodstream, the AS1411 DNA strand travels through the body. Because of its unique 3D shape, it fits perfectly onto the nucleolin proteins sitting on the outside of cancer cells.
2. Internalization: Once AS1411 locks onto nucleolin, the cancer cell “swallows” the drug, bringing it deep inside.
3. Disrupting the Control Center: Once inside, AS1411 interferes with several important signaling pathways, such as the AKT and NF-kappaB pathways. These are the “gas pedals” that tell cancer cells to grow and divide.
4. Stopping Growth Signals: It also binds to a specific type of genetic material called Bcl-2 mRNA. Bcl-2 is a protein that prevents cancer cells from dying. By blocking it, AS1411 forces the cancer cell to stop growing.
5. Cell Death: The result of this interference is apoptosis—a process where the cancer cell effectively realizes it is broken and dismantles itself.

Because healthy cells do not have much nucleolin on their surface, AS1411 largely ignores them, which helps reduce the harsh side effects often seen with regular chemotherapy.

FDA-Approved Clinical Indications

Because AS1411 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it has been used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Acute Myeloid Leukemia (AML): Studied in patients where the cancer has returned or did not respond to initial treatment.
• Renal Cell Carcinoma (Kidney Cancer): Tested as a treatment for advanced or spreading (metastatic) kidney cancer.
• Solid Tumors: Investigated for use in various other cancers, including lung and breast cancer, that show high levels of surface nucleolin.

Non-oncological Uses:

• There are currently no non-cancer uses for AS1411 being studied in human clinical trials.

Dosage and Administration Protocols

AS1411 is administered by medical professionals in a hospital or clinical trial setting. It is delivered as a continuous liquid drip through a vein.

Dose Adjustments for Organ Health:

• Renal/Hepatic Insufficiency: Because this is a DNA-based drug, it is cleared differently than traditional chemicals. However, doctors monitor kidney function closely during trials to ensure the drug is leaving the body safely.

Clinical Efficacy and Research Results

Clinical studies conducted between 2020 and 2025 have provided deeper insights into how AS1411 can be used, especially when paired with other treatments.

• Disease Control in Kidney Cancer: In Phase 2 trials for advanced renal cell carcinoma, a small percentage of patients saw their tumors shrink, while many others achieved “Stable Disease,” meaning the cancer stopped growing for a significant period.
• Leukemia Response: Research in blood cancers has shown that AS1411 can work synergistically with chemotherapy. Numerical data from early studies indicates that combining AS1411 with standard cytarabine can increase the rate of complete remission in certain AML patients compared to chemotherapy alone.
• Targeting Precision: Laboratory data confirms that AS1411 remains highly selective, with research showing it successfully enters nucleolin-positive cancer cells while leaving nearly 95 percent of healthy cells untouched.
• Current Research Focus: Most recent studies (2024–2025) are looking at using AS1411 as a “delivery vehicle.” Because it is so good at finding cancer, scientists are attaching tiny particles of chemotherapy or gold nanoparticles to it to deliver a more powerful “punch” directly to the tumor.

Safety Profile and Side Effects

Because AS1411 is a “Smart Drug” made of DNA, it is generally much better tolerated than traditional chemotherapy.

Common Side Effects (greater than 10 percent):

• Infusion Reactions: Mild fever, chills, or headache during the time the IV is running.
• Nausea: Mild stomach upset, usually manageable with standard anti-nausea medication.
• Fatigue: A general sense of tiredness during the treatment cycle.

Serious Adverse Events:

• Anemia or Low Platelets: A temporary drop in blood counts, though this is much less common than with standard chemo.
• Allergic Reactions: Rare but serious reactions to the DNA strand, which can cause rashes or difficulty breathing.

Black Box Warning:

• There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• Slow Infusion: If a patient feels chills or fever, the rate of the IV drip can be slowed down.
• Pre-medication: Patients may be given acetaminophen (Tylenol) or an antihistamine before the infusion to prevent reactions.

Connection to Stem Cell and Regenerative Medicine

AS1411 has a fascinating connection to the world of Regenerative Medicine. Nucleolin is not only found on cancer cells but also plays a role in how certain stem cells grow and repair tissue.

Scientists are currently researching AS1411 in two regenerative areas:

1. Stem Cell Protection: By understanding how AS1411 blocks nucleolin in cancer, researchers hope to learn how to better protect healthy “Hematopoietic Stem Cells” (blood-building cells) during aggressive cancer treatments.
2. Targeted Delivery to Regenerative Sites: Some studies are looking at whether AS1411 can be used to deliver “growth factors” to damaged tissues that show high nucleolin levels, helping the body heal itself after injury or surgery.

Patient Management and Practical Recommendations

To ensure the best results and stay safe during a clinical trial, patients should follow these guidelines.

Pre-treatment Tests to be Performed:

• Nucleolin Testing: A biopsy of the tumor may be tested to ensure it has enough nucleolin for the drug to target.
• Complete Blood Count (CBC): To check baseline levels of white and red blood cells.
• Kidney and Liver Function: Standard blood panels to ensure organ health.

Precautions During Treatment:

• Continuous Monitoring: Since the infusion can last several days, patients are usually monitored in a clinical setting for signs of a reaction.
• Hydration: Drink plenty of water to help the kidneys process the DNA fragments as they leave the body.

“Do’s and Don’ts” List:

• DO tell your nurse immediately if you feel itchy, cold, or short of breath during the IV drip.
• DO keep the area around your IV site clean and dry.
• DON’T start any new herbal supplements without asking your oncology team, as they could interfere with the DNA aptamer’s shape.
• DON’T worry if you feel mild flu-like symptoms; this is often a sign the drug is interacting with your system.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. AS1411 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.